Crimson staff writer
Thamini Vijeyasingam
Latest Content
Nurses at Dana-Farber Foxborough Ask for Equal Pay to Their MGB Counterparts
Nurses at the Dana-Farber Cancer Institute’s Foxborough campus sent a letter on Friday asking DFCI to eliminate their pay disparity with Mass General Brigham nurses working in the same building.
Eversource Proposes 13% Increase in Gas Rates This Winter
Last winter, Eversource customers saw a historically high price increase in their gas bill. This year is shaping up to be even more expensive.
How Alumni Entrepreneurs Are Trying to Redefine Harvard’s Reputation in the Startup World
At the inaugural Harvard Alumni Entrepreneurs Startup World Cup regionals on Sep. 12, Harvard graduates from 12 finalist startups made pitches for the chance to be sent to the championship round in San Francisco.
Cambridge’s Biotech Industry Threatened by New H-1B Visa Fee
12,000 international workers uphold Massachusetts’s booming technology and biotech industries — including more than 1,000 workers in Cambridge. But new fees on H-1B visas could soon cripple everything from start-ups to big pharma companies in Kendall Square.
Experts Have Reservations About Proposed MGB-CVS Primary Care Clinics
On a weekday morning before work, a pharma executive, a busy student, and a small business owner all walk into a CVS — not for toothpaste or prescriptions, but for a primary care appointment.
How Harvard Lost the JFK Library
In 1963, one month before his assassination, President John F. Kennedy ’40 visited Harvard to choose a site for his presidential library and archives. But after years of local controversy, the JFK library at Harvard never came to be.
Napster Sparks Debate About Music Piracy at Harvard
When Napster was founded in May 1999, students across the country jumped at the opportunity to download their favorite music without the hassle of buying a new CD. But for universities, the novel technology posed a new problem: legal threats from the music industry.
Harvard Built the Biotech Industry in Cambridge, Then Let It Go. Now It Wants Back In.
Over the decades, Kendall Square has become a hub of biotech innovation and a popular location for up and coming life sciences firms. Now, a Harvard-backed Allston is entering the Cambridge biotech scene.
New Cancer Hospital for Dana Farber Leaves Healthcare Experts Skeptical
When the Dana Farber Cancer Institute announced that it was opening a new, $1.7 billion, 300-bed inpatient cancer hospital in 2028 along with Beth Israel Deaconess Hospital, the announcement seemed to promise good news for the region. But healthcare experts aren’t so sure.
FDA Layoffs, Funding Cuts Cast Shadow Over Biopharma Industry
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon expected to pull back from the biotech industry, representing a blow to a primary engine of the Boston area’s economic growth.